How has Supernus Pharmaceuticals's other noncash income (expense) changed year-over-year?

Supernus Pharmaceuticals's other noncash income (expense) increased by 40.3% year-over-year, from -$476K to -$284K.

What does other noncash income (expense) mean?

This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.

Supernus Pharmaceuticals SUPN Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

Amneal Pharmaceuticals, Inc.AMRX

-$1.49M-13.2%

Bausch + LombBLCO

$0-100%

AbbVieABBV

——

Jazz PharmaceuticalsJAZZ

——

Praxis Precision Medicines, Inc.PRAX

——

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's other noncash income (expense)?: Supernus Pharmaceuticals (SUPN) reported other noncash income (expense) of -$284K in Q1 2026.
How has Supernus Pharmaceuticals's other noncash income (expense) changed year-over-year?: Supernus Pharmaceuticals's other noncash income (expense) increased by 40.3% year-over-year, from -$476K to -$284K.
What does other noncash income (expense) mean?: This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.